We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc Q4 Earnings: Can Integrated Care Strength Save Profits?
Read MoreHide Full Article
Key Takeaways
TDOC is expected to post a Q4 loss of 19 cents per share on $633.91M in revenue.
Integrated Care members are seen up 9.1%, with segment EBITDA rising 20.9% year over year.
BetterHelp revenue is projected to fall 6.2%, with paying users down 5% in Q4.
Teladoc Health, Inc. (TDOC - Free Report) is set to report fourth-quarter 2025 results on Feb. 25, 2026, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s bottom line is currently pegged at a loss of 19 cents per shareon revenues of $633.91 million.
The fourth-quarter earnings estimate has improved by a penny over the past 60 days. The bottom-line projection indicates year-over-year improvement of 32.1%. However, the Zacks Consensus Estimate for quarterly revenues implies a year-over-year decrease of 1%.
Image Source: Zacks Investment Research
For 2025, the Zacks Consensus Estimate for Teladoc Health’s revenues is pegged at $2.52 billion, implying a decline of 1.9% year over year. But the consensus mark for 2025 EPS is pegged at a loss of $1.20, implying an improvement of 79.6%, year over year.
Teladoc Health’s earnings beat estimates in three of the last four quarters and missed once, with the average surprise being 14.5%. This is depicted in the figure below.
Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
TDOC has an Earnings ESP of 0.00% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate for fourth-quarter Access fees revenues indicates 1.3% year-over-year decline. While revenues from the U.S. operations are expected to have declined in the quarter, the same from International operations are expected to have increased, partially offsetting the negatives.
The consensus mark for revenue from BetterHelp signals a 6.2% fall from a year ago. BetterHelp paying users are expected to have declined 5% in the fourth quarter. The Zacks Consensus Estimate for fourth-quarter adjusted EBITDA from the segment indicates 28.9% year-over-year decline.
The estimate for U.S. Integrated Care members predicts 9.1% increase year over year. Adjusted EBITDA from Integrated Care is expected to have jumped 20.9%. The company expects overall adjusted EBITDA to lie between $73 million and $90 million.
For the full year 2025, it expects free cash flow to be within $170-$185 million.
How Did Other Stocks Perform?
Here are some companies in the broader Medical space that have already reported earnings for this quarter: CVS Health Corporation (CVS - Free Report) and Doximity, Inc. (DOCS - Free Report) .
CVS Health posted fourth-quarter 2025 adjusted EPS of $1.09, down 8.4% year over year. The metric, however, topped the Zacks Consensus Estimate by 10.1%. Revenues rose 8.2% year over year to $105.69 billion. CVS Health’s revenues rose 8.2% year over year to $105.69 billion.
Doximity delivered adjusted EPS of 46 cents in the third quarter of fiscal 2026, which increased 2.2% year over year and surpassed the Zacks Consensus Estimate by 4.5%. Doximity registered revenues of $185.1 million in the fiscal third quarter, up 10% year over year.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
Teladoc Q4 Earnings: Can Integrated Care Strength Save Profits?
Key Takeaways
Teladoc Health, Inc. (TDOC - Free Report) is set to report fourth-quarter 2025 results on Feb. 25, 2026, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s bottom line is currently pegged at a loss of 19 cents per shareon revenues of $633.91 million.
The fourth-quarter earnings estimate has improved by a penny over the past 60 days. The bottom-line projection indicates year-over-year improvement of 32.1%. However, the Zacks Consensus Estimate for quarterly revenues implies a year-over-year decrease of 1%.
For 2025, the Zacks Consensus Estimate for Teladoc Health’s revenues is pegged at $2.52 billion, implying a decline of 1.9% year over year. But the consensus mark for 2025 EPS is pegged at a loss of $1.20, implying an improvement of 79.6%, year over year.
Teladoc Health’s earnings beat estimates in three of the last four quarters and missed once, with the average surprise being 14.5%. This is depicted in the figure below.
Teladoc Health, Inc. Price and EPS Surprise
Teladoc Health, Inc. price-eps-surprise | Teladoc Health, Inc. Quote
Q4 Earnings Whispers for Teladoc Health
Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
TDOC has an Earnings ESP of 0.00% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
You can see the complete list of today’s Zacks #1 Rank stocks here.
What’s Shaping TDOC’s Q4 Results?
The Zacks Consensus Estimate for fourth-quarter Access fees revenues indicates 1.3% year-over-year decline. While revenues from the U.S. operations are expected to have declined in the quarter, the same from International operations are expected to have increased, partially offsetting the negatives.
The consensus mark for revenue from BetterHelp signals a 6.2% fall from a year ago. BetterHelp paying users are expected to have declined 5% in the fourth quarter. The Zacks Consensus Estimate for fourth-quarter adjusted EBITDA from the segment indicates 28.9% year-over-year decline.
The estimate for U.S. Integrated Care members predicts 9.1% increase year over year. Adjusted EBITDA from Integrated Care is expected to have jumped 20.9%. The company expects overall adjusted EBITDA to lie between $73 million and $90 million.
For the full year 2025, it expects free cash flow to be within $170-$185 million.
How Did Other Stocks Perform?
Here are some companies in the broader Medical space that have already reported earnings for this quarter: CVS Health Corporation (CVS - Free Report) and Doximity, Inc. (DOCS - Free Report) .
CVS Health posted fourth-quarter 2025 adjusted EPS of $1.09, down 8.4% year over year. The metric, however, topped the Zacks Consensus Estimate by 10.1%. Revenues rose 8.2% year over year to $105.69 billion. CVS Health’s revenues rose 8.2% year over year to $105.69 billion.
Doximity delivered adjusted EPS of 46 cents in the third quarter of fiscal 2026, which increased 2.2% year over year and surpassed the Zacks Consensus Estimate by 4.5%. Doximity registered revenues of $185.1 million in the fiscal third quarter, up 10% year over year.